Concepedia

Shyamala Navada

SN

14

Publications

629

Citations

13

H-Index

1986

Active since

Affiliations

Icahn School of Medicine at Mount Sinai(Current)

Onconova Therapeutics (United States)

The University of Texas MD Anderson Cancer Center

Hôpital Saint-Louis

Université Paris Cité

Shyamala Navada is an author at Icahn School of Medicine at Mount Sinai specializing in medicine, hematology, and pharmacotherapy.

Top concepts

MedicineHematologyHealthPharmacotherapyOncologyPathologyPharmacologyCancer ResearchRadiation OncologyCell Transplantation

Publications per year

1986–2023

14

Publications

14

Temporal trends in small cell lung cancer: Analysis of the national Surveillance, Epidemiology, and End-Results (SEER) database

Shyamala Navada, P H Lai, Ann G. Schwartz et al. · Journal of Clinical Oncology · 2006 · 131 citations

Research Interest, Epidemiology, Cancer Epidemiology +15

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

Uwe Platzbecker, Valeria Santini, Pierre Fenaux et al. · The Lancet · 2023 · 118 citations

Hematological Malignancy, Thrombosis, Erythropoiesis-stimulating Agents +9

Therapeutic options for patients with myelofibrosis in blast phase

John Mascarenhas, Shyamala Navada, Adriana K. Malone et al. · Leukemia Research · 2010 · 64 citations

Hematological Malignancy, Antifibrotic Therapy, Hematology +7

Central Nervous System Involvement in Blue-Rubber-Bleb-Nevus Syndrome

Saty Satya‐Murti, Shyamala Navada, Frederick A. Eames · Archives of Neurology · 1986 · 53 citations

Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies

Jonathan Feld, Douglas Tremblay, Mikaela Dougherty et al. · HemaSphere · 2021 · 49 citations · Full text

Rows per page

1–5 of 14